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CASE PRESENTATION
A 69-year-old man was admitted to hospital for the
evaluation of refractory hypokalemia and metabolic
alkalosis. The patient had a 1-year history of a stage
pT4N0M1 non-small cell squamous lung carcinoma
(NSCLC) that was managed by Pemetrexed (Alimta
500 mg/m2 every 21 days) for the last 6 months. The
patient had a 45-pack/y history of smoking without
history of alcohol abuse, hypertension, or diabetes
mellitus. He was married, had 2 children without health
problems and used to work as a truck driver. He had no
family history of cancer or metabolic problems. He was in
his usual state of health until 1 month before admission.
His medication list contained only paracetamol every 6 h.
Two weeks before admission, he was examined in the
emergency department when his family noticed increasing
muscle weakness. On admission in nephrology, blood
pressure was 170/90 mm Hg, and heart rate was 76 beats
per min. There was no peripheral edema, and his mucous
membranes were dry. Skin color had recently become
generally darker as confirmed by the patient. Cardiovascular
and chest examination were unremarkable. Abdominal
examination showed no central obesity, nor striae. Neurolo-
gical examination showed normal reflexes and no localized
sensory deficits. Bilateral proximal muscle weakness was
noted: 4/5 and 3/5 in upper and lower limbs respectively.
Routine peripheral blood and biochemical examination
revealed hyperleukocytosis, hypokalemia, metabolic alkalosis,
and hyperglycemia. Clinical and laboratory values are listed
in Table 1. The patient was managed with oral and
intravenous potassium supplementation without improve-
ment. The primary diagnosis was severe dehydration
associated with contraction metabolic alkalosis, hypokalemia,
hypertension, and type 2 diabetes mellitus (fasting blood
sugar 11 mmol/l with glycosuria at 18.6 mmol/l). Supportive
treatments included hydration, potassium supplementation,
antihypertensive, and oral antidiabetic medications. His
alkalosis and hypokalemia partially improved. Endocrine
laboratory studies were performed; results are listed in
Table 2. Doppler ultrasound study of the renal arteries and
adrenal computed tomography (CT) scan were performed.
CLINICAL DIAGNOSIS
In front of a renal hypokalemia associated with hypertension,
excess mineralocorticoids should be evoked including
primary and secondary hyperaldosteronism or pseudohyper-
aldosteronism (algorithm 1). As aldosterone and renin level
were normal, primary and secondary hyperaldosteronism
could be ruled out. In what concerns the third heterogenous
group of pseudohyperaldosteronism, Liddle’s syndrome and
congenital adrenal hyperplasia can be ruled out because of
the late occurrence of signs and absence of suggestive family
history. There were no liquorice intake reported by the
patient, furthermore these patients usually have markedly
lowered renin aldosterone levels. The diagnosis of Cushing
syndrome (CS) became then plausible.
Markedly elevated serum cortisol (62.7mg/100 ml), adreno-
corticotropic hormone (ACTH) level (380 pg/ml), and
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urine-free cortisol excretion rates (15,576mg/24 h) were
found. An overnight dexamethasone suppression test
(8 mg) reduced plasma cortisol levels to 61.2% of baseline
values. CS was made. The generation and maintenance of
hypokalemia, metabolic alkalosis, and hypertension in this
patient were likely the result of sustained activation of
circulating cortisol. Abdominal and pelvic CT scans showed
normal adrenal glands and confirm previously known
hepatic metastases. Brain magnetic resonance imaging
(MRI) showed normal pituitary gland and no cerebral
metastases. These results supported the diagnosis of ectopic
ACTH secretion.
CLINICAL FOLLOW-UP
The patient was first managed with spironolactone and
potassium supplementation reaching subnormal serum
potassium (3.2 mmol/l) and bicarbonates (31 mmol/l) values,
but he had no remission. He was then treated with
metyrapone to counteract ectopic ACTH production. At 1
week after switching spironolactone for amiloride 10 mg and
metyrapone 1000 mg/d in accordance to endocrine tests, he
made a dramatic recovery: serum potassium levels increased
to 4.1 mmol/l with serum carbon dioxide levels decreasing to
27 mmol/l. Hypertension control (average 120–130 mm Hg
systolic blood pressure) was obtained by amlodipine 10 mg/d
in addition to amiloride. Glycemic control was partial
(treated fasting blood sugar 7.2 mmol/l) using repaglinide
1 mg TID (Novonorm).
DISCUSSION
We described a case of CS. Because he had no pituitary
adenoma and primary adrenal disorders, non-small-cell lung
cancer (NSCLC) was suspected as the source of the excess
ACTH.
Clinical aspects of CS
The name of Harvey Cushing (1869–1939) was immortalized
in the history of medicine, by his discovery, in 1912, of
Cushing’s disease, an endocrine syndrome caused by a
malfunction of the pituitary gland.1 CS is characterized by
truncal obesity with ‘moon face’, facial plethora, ‘buffalo
hump’ but loss of subcutaneous fat, purplish abdominal
striae, ecchymoses and proximal myopathy, accompanied by
nonspecific symptoms like edema, hypertension, fatigability
Table 1 | Clinical and laboratory values
Values
Before admission
Parameters Week 8 Week 4 Week 2 Admission References
Blood pressure (mm Hg) 130/70 163/82 170/95 160/93
Serum parameters
Sodium 139 141 142 149 132–145 (mmol/l)
Potassium 4.10 2.9 2.6 2.9 3.6–5.0 (mmol/l)
Chloride 105 100 97 102 95–105 (mmol/l)
Bicarbonate 29 35 36 36 22–29 (mmol/l)
Glucose 5 9.7 NA 10.8 3.9–5.8 (mmol/l)
Calcium 2.32 2.17 2.19 2.25 2.10–2.65 (mmol/l)
Phosphorus 1.03 NA 0.88 0.66 0.80–1.40 (mmol/l)
Uric acid NA NA NA 136 200–420 (mmol/l)
Magnesium 0.82 NA 0.85 0.80 0.74–0.85 (mmol/l)
Urea 4.8 3.2 3.5 4.10 2.5–7 (mmol/l)
Creatinine 0.85 0.92 0.89 0.68 62–106 (mg/dl)
Osmolality NA NA NA 314 280–300 (mOsm/kg)
White blood cell count 6300 14,900 9900 8260 4000–7000 per ml
Arterial blood pH NA NA 7.52 7.50 7.38–7.42
Arterial PCO2 NA NA 41.9 40.1 38–42 (mm Hg)
Urine parameters
Sodium NA NA 109 82 100–200 (mmol/l)
Potassium NA NA 40 48 50–130 (mmol/l)
Osmolality NA NA NA 460 100–1400 (mOsm/kg)
NA, not applicable.
Table 2 | Endocrine laboratory values
Parameters Values References
Serum
Calcitonin o5 0–5 ng/l
TSHus 0.61 0.1–4 mU/l
Parathormone 60.2 12–65 pg/ml
Aldosterone 19 12–125 pg/ml
Renin 2.5 3.5–19 pg/ml
Cortisol
Baseline 8 h 63.7 5–25 mg/dl
Baseline 16 h 55.6 2.5–12.5mg/dl
After dexamethasone suppression test 47.8
ACTH
Baseline 380 10–45 pg/ml
After dexamethasone suppression test 432
Urines
Urinary free cortisol by HPLC 15,576 11.1–126.3 (mg/24 h)
ACTH, adrenocorticotropic hormone; HPLC, high-performance liquid
chromatography.
116 Kidney International (2009) 76, 115–120
t h e r e n a l c o n s u l t H Izzedine et al.: Hypokalemia, metabolic alkalosis, and hypertension
and weakness, hirsutism, hyperpigmentation, diabetes melli-
tus, and osteoporosis. Hyperpigmentation is due to the
melanotropic activity of ACTH. Loss of potassium, retention
of sodium with subsequent hypertension and hyporeninemia
are the consequences of ‘apparent’ mineralocorticoid excess
(Figure 1).
Tumors that paraneoplastically synthesize ACTH are far
more likely to be malignant than pituitary tumors, with the
consequence of rapid development of hypercortisolism.
Exposure to high levels of glucocorticoids, mineralocorti-
coids, and adrenal androgens may therefore develop within a
short time, and classical stigmata of CS may still be absent
when this disease reaches its power to limit life. Hence, there
are subtle clinical differences in patients with primary
Cushing’s disease and CS in excess ACTH secretion. Purple
striae and buffalo hump are infrequent and the entire
spectrum of features associated with ACTH excess are rarely
seen in patients with underlying cancer.2 Hypokalemia and
accompanying metabolic alkalosis are more common in
ectopic ACTH syndrome than other forms of CS. Hyper-
tensive crises and profound loss of potassium may lead to
cardiac and vascular complications, including ventricular
arrhythmias.3 In addition, polyglobulia with thrombocytosis
and leukocytosis are typical signs for ectopic ACTH
production. Finally marked suppression of the immune
system may cause severe infections, which easily can lead to
septicemia and opportunistic infections.
When ACTH-dependent CS is diagnosed, it is necessary to
confirm or rule out ectopic ACTH production based on
several diagnostic tests such as 24-h urine-free cortisol levels
or the dexamethasone suppression. On another hand,
paraneoplastic syndrome should be strongly suspected over
primary CS in the setting of lung cancer.
Diagnosis of CS
CS is most likely when cortisol levels at midnight are higher
than 5 mg/100 ml, when cortisol levels are higher than 1.4 mg/
100 ml in the combined dexamethasone-corticotropin-releas-
ing hormone test, when there is elevation of cortisol and
ACTH after administration of 1-desamino-8-D-arginine-
vasopressin (DDAVP), or when there is no elevation of
ACTH and cortisol during an insulin-induced hypoglycemia.
Suppressed ACTH levels are found when the adrenals are the
source of hypercortisolism. CT or MRI are helpful to identify
adrenal tumors or enlargement of the adrenal gland. Normal
or even elevated ACTH levels are an argument for ACTH-
dependent CS. In ACTH-dependent CS, the source of ACTH
secretion has to be identified. If it is of pituitary origin,
usually there is a rise of ACTH following corticotropin-
releasing hormone administration and a suppression of
ACTH and cortisol below 50% of basal values after 8 mg of
dexamethasone. If central CS is most likely, an MRI of the
pituitary should be performed. If ectopic ACTH syndrome is
suspected, other laboratory results can contribute to clarify
this diagnosis and include chromogranin A, plasma metane-
phrines, neuron-specific enolase, calcitonin, and cyfra.3
Imaging techniques include CT and/or MRI of thorax and
abdomen and sometimes even an octreotide scan.
In our patient, a primary pituitary source was excluded
based on laboratory and imaging studies. In this patient,
plasma ACTH levels were markedly elevated (Table 2). Over-
night administration of dexamethasone (8 mg) reduced the
plasma cortisol level to 61.2% of baseline. (reduced by 38.8%).
With overnight dexamethasone testing, a decrease in
cortisol level to less than 50% of baseline is indicative of
pituitary-dependent disease. A negative response is consid-
ered lack of suppression to less than 50% of baseline and can
occur with adrenal or ectopic tumor production.4 Overnight
dexamethasone testing has an approximate sensitivity of
57–92% and a specificity of 57–100% in diagnosing pituitary
disease.5 It was found that precursors of ACTH were
markedly elevated in patients with ectopic ACTH syndrome,
in contrast to patients with Cushing’s disease, and that the
concentration of ACTH precursors correlated with plasma
cortisol levels in patients with ectopic ACTH syndrome.6
Otherwise, aggressive pituitary tumors producing high
molecular weight adrenocorticotropin-related peptides have
been described, presenting both with and without the clinical
features of CS.7,8
The cortisol level in our patient was partially suppressed
(38.8% decrease) with an overnight dose of dexamethasone
(8 mg), but only to 61.2% of baseline that was not enough to
substantiate a positive response. This degree of suppression is
consistent with an ectopic source of ACTH secretion. In addition,
normal brain MRI findings essentially excluded pituitary or
hypothalamic pathological states. Although NSCLC was infre-
quently associated with ectopic ACTH secretion, it is likely to be
the cause of Paraneoplastic Cushing syndrome in our patient.
To date, immunohistological staining of suspected ectopic
ACTH-secreting tumors has rarely shown hormone immuno-
reactivity. Evidence suggests that ACTH levels correlate with
the degree of metastasis or rapid growth.9 Immuno-
cytochemistry was performed on 18 tumors causing ectopic
CS. In that study, patients were divided into two groups;
those with clinical signs of an underlying tumor (group 1)
and those with occult tumors not detected by radiological
examination (group 2). Of note, there was one pancreatic
endocrine tumor in each group and no prostate carcinomas
in either group. Rapidly growing tumors with widespread
metastases found in group 1 were associated with the greatest
ACTH levels (662–2340 ng/l). Conversely, occult tumors in
group 2 were associated with the lowest ACTH levels
(82–399 ng/l).9 On the basis of this observation, it is unlikely
that our patient, who showed extremely high levels of ACTH
(41300 pg/100 ml) had an occult tumor. The rapid onset of
our patient’s illness and excessively elevated ACTH levels
were not indicative of a slow-growing tumor that might not
be detected by CT scan or MRI. Thus, by exclusion, we
believe that the high-grade, widely metastatic, prostatic
tumor could have been responsible for the ectopic produc-
tion of ACTH, although we cannot prove this point with
absolute certainty.
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CT and MRI are the best imaging techniques for tumor
localization they can identify lesions with diameters less than
0.5 cm, and their sensitivity approaches 100%.10,11 However,
because these tumors can remain occult, octreotide scinti-
graphy may be indicated to identify them.
Pathophysiology of hypokalemic metabolic alkalosis. The
pathophysiology of ectopic adrenocorticotropin syndrome in
patients with cancer includes ectopic ACTH production,
increased production of the ACTH precursor propiomela-
nocortin, and increased conversion of propiomelanocortin to
ACTH. Up to 50% of small-cell lung cancer (SCLC) can be
associated with ectopic ACTH production, but only 2% to
10% have clinically significant disease. Unlike syndrome of
inappropriate antidiuretic hormone (SIADH), patients with
ectopic ACTH secretion (EAS) from SCLC have poorer
prognosis.12
Glucocorticoids affect a variety of renal functions.
Metabolic alkalosis and potassium depletion are the two
most common acid base and electrolyte abnormalities
associated with glucocorticoid excess. These are predomi-
nantly mediated by the direct effects of glucocorticoids in the
kidney. The receptors for glucocorticoids are expressed in the
proximal tubule and collecting ducts. Mineralocorticoid
receptors are absent in the proximal tubule and are
exclusively expressed in distal nephron segments. In the
proximal tubule, glucocorticoids have been shown to have a
direct effect on the luminal Naþ /Hþ exchanger.
Approximately 80% of the filtered load of HCO3
 is
reabsorbed in the proximal tubule by a process of active acid
secretion by the luminal membrane. The major mechanism
for the transport of HCO3
 across the basolateral membrane
is by the electrogenic Naþ :3HCO3
 co-transporter (NBC).
Algorithm 1: Diagnostic evaluation of hypokalemia 
Serum K+ <3.5 mEq/l
Urine K+ ?  
>20 mEq/24 h < 20 mEq/24 h
Renal K loss Skin and/or gastrointestinal K loss 
Hypomagnesemia 
Yes No
Hypomagnesemia- Serum bicarbonate
induced hypokalemia
         Normal or high  Low 
Blood pressure? Renal tubular acidosis (type 1 of 2) 
Ureterosigmoidostomy
Diabetic ketoacidosis
Hypertensive Normotensive
Renin (R) Aldosterone (H) axis Urine Cl– ?
High Al High Al Low Al  Normal Al < 20 mEq/24 h >20 mEq/24 h  
Low R High R Low R Normal R 
Primary Secondary Pseudo-hyper Cushing’s Vomiting Diuretics 
Hyper- Hyperaldo- aldosteronism syndrome Nasogastric drainage Bartter’s syndrome
aldoste- Post-hypercapnia  Gitelman’s
ronism - malignant HT syndrome 
- renovascular HT
- Renin-secreting
tumor - Liddle’s syndrome 
- Congenital adrenal hyperplasia 
steronism
- exogenous 
mineralocorticoids
- glycyrrhizic acid  
Figure 1 | Diagnostic algorithm. Defining the cause of hypokalemia starts by measuring urinary K level. If inappropriately increased, the
existence of hypertension suggests either secondary or primary hyperaldosteronism. Clinicians should also look for excess glucocorticoids.
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Recent molecular cloning experiments have identified the
existence of three NBC isoforms (NBC-1, NBC-2, and
NBC-3).13 Specifically, NBC-1 may be upregulated in
metabolic acidosis and potassium depletion and in response
to glucocorticoid excess and may be downregulated in
response to HCO3
 loading or alkalosis.14 Glucocorticoids
but not mineralocorticoids enhance both mRNA expression
and functional activity of renal proximal tubule NBC-1.
Enhanced NBC activity could result in increased HCO3

reabsorption in proximal tubule in pathophysiological states
associated with increased glucocorticoid production. Gluco-
corticoid excess is associated with potassium depletion or
hypokalemia. This effect is predominantly thought to be by
the ‘spillover’ effect of glucocorticoids onto the mineralo-
corticoid receptors, with resulting enhanced potassium
secretion in the cortical collecting duct. Potassium depriva-
tion increases HCO3
 reabsorption in proximal tubule by
enhancing NBC-1 expression and activity. The results further
indicate that by inducing NBC-1 expression in medullary
thick ascending limb (mTAL) and inner medullary collecting
duct (IMCD), potassium deprivation enhances HCO3

reabsorption in these nephron segments. It becomes apparent
that upregulation of NBC-1 is an early event and precedes the
onset of hypokalemia,15 indicating that the signal responsible
for enhanced NBC-1 expression is likely activated by
intracellular potassium depletion rather than hypokalemia.16
Epidemiology and causes of Paraneoplastic CS. Ectopic
ACTH production is defined as the secretion of ACTH from a
tumor outside the pituitary gland. The association between
CS and tumors of ‘non-endocrine’ organs dates back to
1928.17 ‘Ectopic’ hormone production is said to account for
between 12 and 25% of cases of CS, and small-cell
carcinomas are the most commonly recognized tumor.18
Other causes included nonpituitary neoplasms, mostly of
neuroendocrine origin19 (such as pancreatic islet cell tumors,
bronchial, thymic, and gastrointestinal neuroendocrine
cancers, bronchial adenomas, and medullary carcinomas of
the thyroid or pheochromocytomas5 or carcinomas (such as
hypernephromas, colon cancers, and paragangliomas).
Paraneoplastic CS is frequently seen in patients with
SCLC. However, the incidence of paraneoplastic CS is 5% or
less of all SCLC patients.12 In contrast, paraneoplastic CS is
very rare in NSCLC including adenocarcinoma, and to our
knowledge there are only a few reports of NSCLC associated
with CS.20–22
The present patient had severe ACTH-dependent CS.
Because he had no pituitary adenoma and primary adrenal
disorders, adenocarcinoma of the lung was suspected as the
source of the excess ACTH. An immunohistochemical study
of ACTH with primary or metastatic tumor specimens was
not performed. However, ACTH produced from a neoplasm
has been shown to have a different structure than wild-type
ACTH and the usual immunohistochemical staining with a
polyclonal anti-ACTH antibody may not prove ACTH in
tumor cells.23 Paraneoplastic Cushing syndrome caused by
ectopic ACTH production can cause a poor clinical outcome
due to various complications. SCLC patients with ectopic
ACTH production have a much higher rate of complications
during therapy than patients without ectopic ACTH
production.12,24
Management of paraneoplastic CS. In general, surgery is
the therapy of choice in CS caused by ectopic ACTH
secretion. However, in 30 percent of patients with CS,4
surgery is not a therapeutic option and bilateral adrenalect-
omy is rarely used in refractory cases.25
Treatment of the underlying malignancy is the primary
management of the ectopic ACTH secretion. Medical therapy
for ectopic ACTH production can be accomplished with the
use of steroid synthesis inhibitors, such as ketoconazole,26
mitotane, metyrapone,27 octreotide,28 and aminoglutethe-
mide,29 although successful treatment of the underlying
malignancy is critically needed. Other medical interventions
include potassium replacement and spironolactone.
Ketoconazole (400–1200 mg/day), which acts by blocking
corticosteroid production by inhibiting 17-hydroxylase and
11-hydroxylase, is the therapy of choice because of its low
incidence of side effects. The dose–response relationship
between ketoconazole and cortisol has not been well
described in the literature. Ketoconazole has been reported
to be persistently effective at 200–1200 mg/d, without escape
from suppressive effect for prolonged use.30 Octeotride
suppression of ACTH release has shown efficacy alone and
in combination with ketoconazole.4 An alternative agent is
metyrapone; however, clinical efficacy of this agent is less
than that of ketoconazole, it lacks the antiandrogenic effect of
ketoconazole, and it may cause hypokalemia as a side effect.27
Spironolactone, an aldosterone-receptor antagonist, is used
to decrease urinary potassium wasting secondary to activa-
tion of mineralocorticoid receptors.31
In this patient, potassium replacement and spironolactone
remained insufficient and amiloroide–metyrapone combina-
tion normalized serum potassium level. On another hand,
ketoconazole decreased both cortisol and ACTH levels in
38% of the patients with ectopic ACTH secretion.32
In summary, we described a rare case of paraneoplastic CS
seemingly associated with NSCLC. Early detection and
appropriate treatment for this syndrome remains necessary
even if it does not generally improve the poor clinical
outcome.
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